This article is part of the supplement: Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection .

Poster presentation

Therapeutic drug monitoring of atazanavir in pregnancy

J Lambert¹, LJ Else², V Jackson³, SE Gibbons², M Brennan³, J Kieran¹, J Breiden¹, S Coulter-Smith³ and SH Khoo²

¹  Mater Misericordiae University Hospital and University College Dublin; The Rotunda Hospital, Dublin, Ireland

²  Department of Pharmacology, University of Liverpool, Liverpool, UK

³  The Rotunda Hospital, Dublin, Ireland

corresponding author email

from Ninth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 9–13 November 2008

Journal of the International AIDS Society 2008, 11(Suppl 1):P246doi:10.1186/1758-2652-11-S1-P246

Published:	10 November 2008

First paragraph (this article has no abstract)

Achieving and maintaining an optimal plasma concentration of antiretroviral drugs is essential for minimising the risks of mother-to-child transmission of HIV. However, altered pharmacokinetics during pregnancy means there is a real risk of both under- and over-dosing of medications. The aim of this study is to describe atazanavir/ritonavir (ATV/r) pharmacokinetics during pregnancy.